ShanXi C&Y Pharmaceutical GroupLTD Balance Sheet Health
Financial Health criteria checks 4/6
ShanXi C&Y Pharmaceutical GroupLTD has a total shareholder equity of CN¥803.4M and total debt of CN¥230.4M, which brings its debt-to-equity ratio to 28.7%. Its total assets and total liabilities are CN¥1.5B and CN¥672.9M respectively. ShanXi C&Y Pharmaceutical GroupLTD's EBIT is CN¥37.8M making its interest coverage ratio 1.7. It has cash and short-term investments of CN¥131.9M.
Key information
28.7%
Debt to equity ratio
CN¥230.38m
Debt
| Interest coverage ratio | 1.7x |
| Cash | CN¥131.92m |
| Equity | CN¥803.38m |
| Total liabilities | CN¥672.86m |
| Total assets | CN¥1.48b |
Recent financial health updates
No updates
Recent updates
ShanXi C&Y Pharmaceutical Group Co.,LTD.'s (SZSE:300254) 36% Price Boost Is Out Of Tune With Revenues
May 27
ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues
Mar 25ShanXi C&Y Pharmaceutical Group Co., Ltd.'s (SZSE:300254) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Mar 06Financial Position Analysis
Short Term Liabilities: 300254's short term assets (CN¥417.3M) do not cover its short term liabilities (CN¥447.2M).
Long Term Liabilities: 300254's short term assets (CN¥417.3M) exceed its long term liabilities (CN¥225.6M).
Debt to Equity History and Analysis
Debt Level: 300254's net debt to equity ratio (12.3%) is considered satisfactory.
Reducing Debt: 300254's debt to equity ratio has reduced from 29.4% to 28.7% over the past 5 years.
Debt Coverage: 300254's debt is well covered by operating cash flow (34.7%).
Interest Coverage: 300254's interest payments on its debt are not well covered by EBIT (1.7x coverage).